Everyone buys toothpaste and so they come in shapes and flavors, as pastes and gels, some guard against tooth decay or protect teeth from acid attack, while others that are designed for sensitive teeth. But which toothpastes clean well? Which preserve the tooth enamel? A new evaluation method sheds light on the subject.

Researchers have identified a key factor responsible for declining muscle repair during aging, and discovered how to halt the process in mice - using a common drug. 

There may be good news for the blood donation business; the shelf life of blood has perhaps gotten longer.

In a finding that runs counter to commonly held beliefs about fresh blood being better, a randomized clinical trial shows that acutely ill premature babies who received fresher blood did not fare better than those who received the current standard of care. There was no difference between the two approaches with respect to major organ injury, mortality and infection.

Five percent of men are affected by infertility and some new insights into sperms' swimming skills could shed light on why.

In a new study, researchers have shown how a protein called RABL2 affects the length of sperm tails, crippling their motility (or swimming ability), and decreases sperm production. In laboratory tests, the team found that a mutation in RABL2 resulted in sperm tails that were 17 per cent shorter than normal. Dysfunctioning RABL2 also negatively affected sperm production, resulting in a 50 per cent decrease. 

A neuroprotectant drug has been shown to protect the human brain against the damaging effects of stroke. The clinical trial was a randomized, double blind, multi-center trial that was conducted in Canada and the USA. The study evaluated the effectiveness of NA-1 (Tat-NR2B9c) when it was administered after the onset of small strokes that are incurred by patients who undergo neurointerventional procedures to repair brain aneurysms. This type of small ischemic stroke occurs in over 90% of aneurysm patients after such a procedure, but usually does not cause overt neurological disability. 

New data shared today with Europe's epilepsy community at the 10th European Congress on Epileptology (ECE) in London, demonstrated the efficacy of Fycompa(R) (perampanel) in reducing partial-onset seizures, the most common form of epilepsy, and its effectiveness and flexibility of use as add-on therapy. 

The successful treatment of partial-onset seizures (the most common form of epilepsy) remains a significant challenge in some patients and the incidence of uncontrolled partial epilepsy remains high, despite many existing anti-epileptic drugs (AEDs); between 20 - 40% of patients with epilepsy have remained poorly controlled despite these treatments.[1] The new data supports the use of perampanel as a new therapeutic option for this hard-to-treat patient population.